

# **Multilocus analysis of atopy in Korean children using multifactor-dimensionality reduction**

Heung-Woo Park<sup>1,2</sup>, Eun-Soon Shin<sup>3</sup>, Jong-Eun Lee<sup>3</sup>, Hyouk-Soo Kwon<sup>1,2</sup>, Eunyong Chun<sup>1,2</sup>, Sun-Sin Kim<sup>1,2</sup>, Yoon-Seok Chang<sup>1,2</sup>, Yoon-Keun Kim<sup>1,2,\*</sup>, Kyung-Up Min<sup>1,2</sup>, and You-Young Kim<sup>1,2</sup>, Sang-Heon Cho<sup>1,2</sup>

<sup>1</sup>Department of Internal Medicine, <sup>2</sup>Institute of Allergy and Clinical Immunology, Seoul National University College of Medicine; <sup>3</sup>DNA Link Inc., Seoul, Republic of Korea

\*Current address: Department of Life Science, Pohang University of Science and Technology, Pohang, Republic of Korea

**Running title:** Gene-gene interaction of atopy

**Correspondence and requests for reprints** should be addressed to Sang-Heon Cho, MD, PhD. Department of Internal Medicine, Seoul National University, 28 Yongondong, Chongno-gu, Seoul 110-744, Republic of Korea. E-mail: [shcho@plaza.snu.ac.kr](mailto:shcho@plaza.snu.ac.kr), Fax: 82-2-762-9662, Phone Number: 82-2-2072-2971

**Keywords:** Atopy, Gene-gene interaction, Tumor necrosis factor  $\alpha$ , Vascular endothelial growth factor receptor 2

~~The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in THORAX and any other BMJPGI products and sublicences such use and exploit all subsidiary rights, as set out in our licence.~~

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in [THORAX] editions and any other BMJPG Ltd products to exploit all subsidiary rights, as set out in our licence (<http://thorax.bmjournals.com/ifora/licence.pdf>).

**Abbreviations:**

CV: Cross Validation

**KDR: Kinase insert domain-containing receptor**

MDR: Multifactor dimensionality reduction

VEGF~~R~~: Vascular endothelial growth factor

TNF: Tumor necrosis factor

**SNP: Single nucleotide polymorphism**

## Summary

**Background:** Atopy is considered to be a complex genetic trait and do not follow a simple Mendelian pattern of inheritance. It is now well recognized that gene-gene interactions are important in complex genetic disease.

**Methods:** A total of 2,055 ethnically identical subjects aged from 10 to 18 years living in rural areas on Jeju Island, Korea were randomly recruited. Atopy was defined as a positive skin prick test response to one or more common inhalant allergen. We analyzed gene to gene interactions among 12 polymorphic loci in the 7 candidate genes of atopy using multidimensionality reduction method.

**Results:** A significant interaction was found between V297I in the gene coding vascular endothelial growth factor receptor 2 (~~VEGFR2~~ KDR) and -308G>A in the gene coding ~~TNF $\alpha$~~  tumor necrosis factor  $\alpha$  (TNF) on the risk of atopy, with a cross-validation consistency of 10 of 10 and a prediction error of 35.9% (P = 0.001). Conventional logistic regression also revealed significant interactions between ~~VEGFR2~~ KDR and ~~TNF $\alpha$~~  TNF for atopy. Individuals with the variant allele of -308G>A in ~~TNF $\alpha$~~  TNF (GA or AA) and V297I in ~~VEGFR2~~ KDR (VI or II) had a significant higher risk of atopy [OR (95%CI) = 2.2397 (1.4879-3.5768)].

**Conclusion:** ~~TNF $\alpha$~~  KDR and ~~VEGFR2~~ TNF may synergistically influence on the

development of atopy through gene-gene interaction in Korean children and adolescents.

Atopy is defined as a genetic predisposition to induce enhanced IgE responses to common environmental allergens. It is considered to be a complex genetic trait and thus do not follow a simple Mendelian pattern of inheritance. Instead, the genetic determination of atopy is likely due to several genes, each having a small, possibly synergistic, effect on phenotype. Therefore it is necessary to consider simultaneously the effect of several single nucleotide polymorphism (SNP) genotypes at different loci. Such gene-gene interactions are traditionally evaluated using logistic regression. However procedures for fitting logistic regression model are problematic leading to an increase in type II errors and a decrease in power. In addition, sparseness of the data can be another problem in high dimensions.

To address these problems, multifactor dimensionality reduction or MDR has been developed<sup>1</sup>. MDR is a nonparametric and genetic model-free approach and is able to identify evidence for high-order gene-gene interactions in the absence of any statistically significant independent main effects in simulated data<sup>2,3</sup>. With MDR, gene-gene interactions has been revealed in complex genetic disorders, such as hypertension<sup>4</sup>, type 2 diabetes mellitus<sup>5</sup>, atrial fibrillation<sup>6</sup>, myocardial infarction<sup>7</sup> and asthma<sup>8</sup>.

In the present study, 12 loci in 7 genes proven to be related with atopy or enhanced serum IgE were genotyped in Korean children and adolescents and gene-gene

interaction was examined with MDR.

## Methods

### *Study subjects and atopy definition*

All the subjects enrolled in this study gave written informed consent, and the study protocol was approved by the Institutional review board of Seoul National University Hospital. ~~A total of 2,055 ethnically identical subjects aged from 10 to 18 years living in rural areas on Jeju Island, Korea were randomly recruited.~~ A total of 2,864 ethnically identical subjects aged from 10 to 18 years were randomly recruited through school located on the southern part of Jeju Island in Korea, of whom 2,055 (71.8%) were enrolled in this study. All of them resided in rural area and most of their parents lived by fishing or cultivating fruit trees. Skin prick test with 11 common aeroallergens (*Dermatophagoides pteronyssinus*, *Dermatophagoides farinae*, dog fur, cat fur, *Aspergillus*, *Alternaria*, tree pollen mixture, grass pollen mixture, mugwort, ragweed, and cockroach; Allergopharma, Germany) was performed as previously described<sup>9</sup>. Subjects who had received oral antihistamines during the five days prior to skin prick test or had dermographism were excluded. Atopy was defined as a positive skin prick test response (allergen/histamine ratio > 1.0 plus a mean wheal size > 4 mm) to one or more allergens.

### *Selection of genes and SNPs*

~~Using public databases, e.g. PubMed and Online Mendelian Inheritance in Man (<http://www.ncbi.nlm.nih.gov/Omim/>), we selected 7 candidate genes and 12 SNPs within these genes that have been characterized and potentially associated with atopy and enhanced serum IgE<sup>10-24</sup>. These are listed in Table 1.~~

On the assumption that cytokines play a crucial role in the widely used immunological model that explains the increasing prevalence of atopy by an altered balance between Th1 and Th2 immune responses<sup>10</sup>, we selected 6 cytokine-related candidate genes using public databases, e.g. PubMed and Online Mendelian Inheritance in Man (<http://www.ncbi.nlm.nih.gov/Omim/>). All have been characterized and potentially associated with atopy or enhanced serum IgE in asian population and subsequent studies performed in non-asian population have witnessed this association<sup>11-25</sup>. The only exception was *KDR* (Kinase insert domain-containing receptor) coding vascular endothelial growth factor (VEGF) receptor 2 which, in our previous study, was proven to be associated with increased prevalence of atopy in Korean population<sup>26</sup>. In addition to these cytokine-related genes, *MS4A2* coding high affinity IgE receptor beta subunit (FcεR1B) was included which was also known to be significantly associated with atopy<sup>27,28</sup>. Within these genes, 10 functional SNPs<sup>11,12,14,17,18,29-31</sup> were chosen for analysis. As

for *KDR*, I297V and H472Q were selected because they were located in regions coding for the extracellular fourth and fifth immunoglobulin-like domains and thus possibly alter signaling pathway as discussed in our previous study<sup>26</sup>.

#### *Genotyping*

SNPs were scored using the high throughput single base-pair extension method (SNP-IT™ assay) using an SNPstream25K system, which was customized to automatically genotype DNA samples in 384 well plates and provide a colorimetric readout (Orchid Biosciences, New Jersey, USA) as previously described<sup>25 26</sup>.

#### *Statistical analysis*

Allele frequencies were estimated by gene counting methods and the  $\chi^2$  test was used to examine the Hardy-Weinberg equilibrium. Association between atopy and each 12 loci was made with the Pearson  $\chi^2$  test with use of dominant, recessive and co-dominant genetic models. MDR (version 0.6.2; Computational Genetics Laboratory, Dartmouth Medical School, Hanover, NH; <http://www.epistasis.org>) was done as described previously<sup>1-3,5,8</sup>. Briefly, the data set is divided into ten parts of equal size for 10-fold cross-validation (CV) (9/10 of the data for training and 1/10 of the data for testing).

~~A training set composed of 9/10 of the data used to build the MDR model is selected. The remaining 1/10 of the data is used to compose the testing set.~~ Next, a

set of  $n$  ~~genetic factors~~ SNP polymorphisms is selected which are represented in  $n$ -dimensional space. Then the ratio of cases to controls is calculated for each combination, which is labeled 'high-risk' ( $> 1.0$ ) or 'low-risk' ( $< 1.0$ ). ~~During the model selection process, each multifactor cell class in  $n$ -dimensional space is labeled as high-risk if the ratio of cases to controls meets or exceeds the threshold of 1.0 and as low-risk if the threshold is not exceeded. When the final best model is selected, a model for high-risk and low-risk genotype combinations is formed using an adjusted threshold that is equal to the ratio of cases and controls in the dataset.~~ Consequently,  $n$  dimensional space was reduced to one dimension with two levels.

Among all of the two-factor combinations, a single model that ~~maximizes the cases to controls ratio is selected. This two-locus model has the minimum~~ minimizes classification error is chosen, among the two-locus models. To evaluate the predictive ability of the model, a prediction error is obtained through 10-fold CV. ~~the model is evaluated on the basis of the 1/10 of the data left out for testing. This procedure is done ten times, each time using a different 1/10 of the data for testing.~~ In our study we ~~we~~ set out to detect all two-locus interactions through five-locus interactions due to computation restrictions. ~~The result is a set of models, one for each model size considered.~~ From this set, the model with the combination of loci and/or discrete

environmental factors that maximizes the CV consistency and minimizes the prediction error is selected. ~~CV consistency is a measure of the number of times a particular set of loci and/or factors are identified in each possible 9/10 of the subjects. The proportion of subjects for whom an incorrect prediction was made is the prediction error. When CV consistency is maximal for one model and prediction error is minimal for another, statistical parsimony is used to choose the best model. Thus when the CV metric and the prediction error metric support different models, the model with the fewest loci/factors is selected. Hypothesis testing of this final best model can then be done by evaluating the magnitude of the prediction error.~~ We determined statistical significance of the final best model ~~by comparing the average prediction error from the observed data with the distribution of average prediction errors under the null hypothesis of no associations derived empirically from~~ using 1000 permutations ~~s~~ testing. The entire procedure is repeated for each, generating a distribution of predictive errors and CV consistencies that could be expected by chance alone. The significance of the final model is determined by comparing the predictive error and CV consistency of the final model to the distribution. A P value is extracted for the model by its theoretical location in the distribution. ~~In this study, prediction error is evaluated for the best model identified by MDR in~~

~~each permuted dataset. The null hypothesis was rejected when the upper-tail~~

~~Monte Carlo p value derived from the permutation test was 0.05 or lower.~~ In

addition, logistic regression analysis and  $\chi^2$  tests were performed to confirm the results

from MDR analyses. A P value of less than 0.05 was considered statistically significant.

The detection power of the sample in the present study was 0.8 for atopy, if the

relative risk for atopy in those persons carrying a putative risk allele is set to 2

compared with that in persons without the allele (The exception was S226N in

*IL12B* whose detection power was 0.6).

## Results

### *Study population*

A total of 2,055 children and adolescents were enrolled. The mean age was 14.6 (range; 10-18) and 48.9% of them were male. The characteristics of study population are shown in Table 2. ~~The prevalence of atopy was 37.3% (767 subjects).~~

### *Association between atopy and individual SNP*

All 12 SNPs examined in the present study were in Hardy-Weinberg equilibrium. The minor allele frequencies of SNPs in the present study with comparison to those previously reported are given in table S1 available online at the Thorax website <http://www.thoraxjnl.com/supplemental>. Among them, ~~Fe~~~~R1B~~ MS4A2 E237G ( $P = 0.028$  in a co-dominant model), ~~TNF~~~~α~~ TNF -308G>A [ $P = 0.031$ ; odds ratio (95% CI) = 1.315 (1.024-1.6986) in a dominant model] and ~~VEGFR2~~ KDR V297I [ $P = 0.048$ ; odds ratio (95% CI) = 1.224 (1.004-1.50498) in a dominant model] showed significant association with atopy (Table 3 3).

### *MDR analysis*

Table 3 4 summarizes, for each number of loci evaluated, the average CV consistency and average prediction error obtained from MDR analysis. One two-locus model had a minimum prediction error of 35.93% ( $P = 0.001$ ) and a maximum CV consistency of 10

out of 10. This two-locus model, which included ~~the~~ *TNF* -308G>A ~~promoter SNP in~~  
~~the~~ *TNF* ~~gene~~ and ~~the~~ *KDR* V297I ~~coding non-synonymous SNP in exon 7 of the~~  
~~*VEGFR2* gene~~ (~~Fig 1~~ figure 1) was regarded as the best model.

Logistic regression analysis

A significant interaction between *TNF* -308G>A ~~in~~ *TNF* and *KDR* V297I ~~in~~ *VEGFR2*  
on the risk of atopy was also found by means of logistic regression analysis ( $P < 0.001$ ),  
adjusting for age, sex, passive smoking and family history of allergic disease as  
covariates. Individuals with the variant allele of *TNF* -308G>A ~~in~~ *TNF* (GA or AA)  
and *KDR* V297I ~~in~~ *VEGFR2* (VI or II) had a significant higher risk of atopy [OR  
(96%CI) = 2.30297 (1.4879-3.5768)]. ~~Figure 2~~ Table 5 shows the results.

## Discussion

Perhaps ~~a tough problem ever faced by allergist~~ the toughest problem faced by the allergist is that of identifying genes carrying alleles affecting liability to asthma or atopy from the vast field of potential candidates. The problem becomes even harder if gene-gene interaction must be considered. In the present study, a 2-locus model involving SNPs in ~~TNF $\alpha$~~  TNF and ~~VEGFR2~~ KDR was identified by MDR as being associated with atopy. Moreover this was confirmed again by conventional logistic regression analysis.

So far, some investigators have witnessed gene-gene interactions in asthma or its related phenotypes using traditional procedures for fitting logistic regression models ~~16-15, 26-28~~ 32.

However, logistic regression analysis can be problematic leading to an increase in type II errors and a decrease in power. For example, forward selection is limited because interactions are only tested for those variables that have a statistically significant independent main effect. Those SNPs that have an interaction effect but not a main effect will be missed. Likewise only two SNPs with the strongest evidence for association with asthma phenotypes were selected in the previous studies. On the contrary, MDR is able to identify evidence for high order gene-gene interactions in the absence of the statistically significant independent main effects in diseases<sup>2,3</sup>. There was

no *a priori* assumption on whether there was interaction between any specific combination of SNPs in the present study. Along with this, MDR effectively detected 2-locus interaction among 12 SNPs which showed no significant association with atopy individually after correction for multiple testing. We used 0.016 (0.05/3) as a Bonferroni corrected P value because we analyzed our findings at each locus under three models. The Bonferroni procedure is said to be conservative and thus will be unable to detect some of the actual differences. However, MDR procedure in the present study evidently finds genetic effects on atopy derived by gene-gene interactions which is much stronger than those caused by individual SNP. (~~Association between atopy and individual SNP has become insignificant after multiple comparison).~~

Results of the present study are of particular interesting in that previous studies consistently reported that interaction between IL4RA and IL13 markedly increased an individual's susceptibility to asthma<sup>8,46 15</sup>. Recently, Chan IH and his colleagues showed a significant interaction between I50V in the ~~IL4RA~~ IL4RA and R130Q in the ~~IL13~~ IL13 for asthma which were also included in the present study using MDR analysis<sup>8</sup>. However, like the present study, they failed to demonstrate an interaction between ~~IL4R~~ IL4RA and ~~IL13~~ IL13 for total serum IgE concentration, another important

intermediate phenotype of atopy. Taken together, these findings implied that, although atopy is known to be an important risk factor, additional or different genetic factors are needed for the development of asthma. The present study showed a new insight in the genetic basis for atopy, that is, a significant interaction between V297I in ~~the VEGFR2~~ KDR and -308G>A in ~~the TNF $\alpha$  TNF~~. ~~Vascular endothelial growth factor (VEGF)~~ was originally described as a vascular permeability factor (~~VPF~~) because of its ability to generate tissue edema and ~~S~~subsequently, it was appreciated to be a multifunctional angiogenic regulator that stimulates epithelial cell proliferation, blood vessel formation, and endothelial cell survival.<sup>29 33</sup> ~~VEGFR2~~ VEGF receptor 2 is known to be a major VEGF signaling receptor.<sup>29 33</sup> The ability of cockroach antigen to directly stimulate epithelial VEGF elaboration<sup>29 34</sup> may account for the impressive levels of sensitization that are caused by even low-level exposure to this antigen.<sup>21 35</sup> Moreover, our previous study demonstrated that V297I causing amino acid change in regions in ~~the VEGFR2~~ KDR which is known to be essential for maintaining the high association rate with VEGF and retention of the VEGF on the receptor, was significantly associated with the prevalence of atopy.<sup>22 26</sup> It is plausible that VEGF contributes to the proclivity of individuals to become sensitized to respiratory antigens and thus genetic variation in ~~the VEGFR2~~ KDR may have effects on the development of atopy. Tumour necrosis factor

$\alpha$  (TNF $\alpha$ ) is a potent proinflammatory cytokine that is ~~proven~~ thought to be associated with predisposition to atopy.<sup>33 36</sup> During early maturation of the infant's immune system, TNF $\alpha$  might be produced by antigen-presenting cells, such as monocytes-macrophages, dendritic cells<sup>33 37</sup> and mast cells,<sup>34 38</sup> playing an important role in the interactions between innate and adaptive immunity. Innate immune cytokines, such as TNF $\alpha$ , are likely involved in priming the adaptive immune-humoral responses. Notably, recent evidence has linked TNF $\alpha$  to the development of allergic rhinitis in mice.<sup>34 39</sup> Interestingly, it has been demonstrated that TNF $\alpha$  and VEGF react upon each other in inflammatory site; TNF $\alpha$  induces VEGF<sup>35 40</sup> and *vice versa*.<sup>36 41</sup> Collectively, ~~TNF $\alpha$~~  TNF and ~~VEGFR2~~ KDR may synergistically influence on the development of atopy through gene-gene interaction.

## **Acknowledgements**

This work was supported by the Korea Health 21 R&D Project Grant 03-PJ10-PG13-GD01-0002 and the Clinical Research Center for Chronic Obstructive Airway Disease Grant 0412-CR03-0704-0001 from the Korean Ministry of Health and Welfare.

## References

1. **Hahn LW**, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. *Bioinformatics* 2003;**19**:376-82.
2. **Ritchie MD**, Hahn LW, Roodi N, ~~Bailey LR, Dupont WD, Parl FF, Moore JH~~ **et al.** Multifactor dimensionality reduction reveals high-order interactions among estrogen metabolism genes in sporadic breast cancer. *Am J Hum Genet* 2001;**69**:138-147.
3. **Moore JH**, Williams SW. New strategies for identifying gene-gene interactions in hypertension. *Ann Med* 2002;**34**:88-95.
4. **Williams SM**, Ritchie MD, Phillips JA III, ~~Dawson E, Prince M, Dzhura E~~, et al. Multilocus analysis of hypertension: a hierarchical approach. *Hum Hered* 2004;**57**:28-38.
5. **Cho YM**, Ritchie MD, Moore JH, ~~Park JY, Lee KU, Shin HD~~, et al. Multifactor-dimensionality reduction shows a two-locus interaction associated with type 2 diabetes mellitus. *Diabetologia* 2004;**47**:549-54.
6. **Tsai CT**, Lai LP, Lin JL, ~~Chiang FT, Hwang JJ, Ritchie MD~~, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. *Circulation* 2004;**109**:1640-6.

7. Coffey CS, Hebert PR, Ritchie MD, ~~Krumholz HM, Gaziano JM, Ridker PM~~, et al.

An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation. *BMC Bioinformatics* 2004;5:49-59.

8. Chan IH, Leung TF, Tang NL, ~~Li CY, Sung YM, Wong GW, Wong CK, Lam CW~~.

et al. Gene-gene interactions for asthma and plasma total IgE concentration in Chinese children. *J Allergy Clin Immunol* 2006;117:127-33.

9. Kim YK, Chang YS, Lee MH, ~~Hong SC, Bae JM, Jee YK~~, et al. Role of

environmental exposure to spider mites in the sensitization and the clinical manifestation of asthma and rhinitis in children and adolescents living in rural and urban areas. *Clin Exp Allergy* 2002;32:1305-9.

10. Yazdanbakhsh M, Kreamsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. *Science* 2002;296:490-4.

~~12.~~ 11. Hershey GK, Friedrich MF, Esswein LA, ~~Thomas ML, Chatila TA~~. et al. The

association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. *N Engl J Med* 1997;337:1720-5.

~~13.~~ 12. Risma KA, Wang N, Andrews RP, ~~Cunningham CM, Eriksen MB, Bernstein~~

~~JA, Chakraborty R, Hershey GK~~. et al. V75R576 IL-4 receptor alpha is associated

with allergic asthma and enhanced IL-4 receptor function. *J Immunol* 2002;**169**:1604-10.

~~14.~~ **13.** Heinzmann A, Mao XQ, Akaiwa M, ~~Kreomer RT, Gao PS, Ohshima K, Umeshita R~~ et al. Genetic variants of IL-13 signalling and human asthma and atopy. *Hum Mol Genet* 2000;**9**:549-59.

~~15.~~ **14.** Mitsuyasu H, Izuhara K, Mao XQ, ~~Gao PS, Arinobu Y, Enomoto T,~~ et al. Ile50Val variant of IL4Ra upregulates IgE synthesis and associates with atopic asthma. *Nat Genet* 1998;**19**:119-20.

~~16.~~ **15.** Howard TD, Koppelman GH, Xu J, et al. Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. *Am J Hum Genet* 2002;**70**:230-~~23~~6.

**16.** Leung TF, Tang NL, Chan IH, et al. A polymorphism in the coding region of interleukin-13 gene is associated with atopy but not asthma in Chinese children. *Clin Exp Allergy* 2001;**31**:1515-21.

~~17. Hummelshoj T, Bodtger U, Datta P, Malling HJ, Oturai A, Poulsen LK, Ryder LP, Sorensen PS, Svejgaard E, Svejgaard A. Association between an interleukin-13 promoter polymorphism and atopy. *Eur J Immunogenet.* 2003 ;**30**:355-9.~~

**17.** van der Pouw Kraan TC, van Veen A, Boeijs LC, et al. An IL-13 promoter polymorphism associated with increased risk of allergic asthma. *Genes Immun* 1999;**1**:61-5.

~~18. Liu X, Nickel R, Beyer K, et al. An IL13 coding region variant is associated with a high total serum IgE level and atopic dermatitis in the German multicenter atopy study (MAS-90). *J Allergy Clin Immunol* 2000;106:167-170.~~

18. Vladich FD, Brazille SM, Stern D, et al. IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation. *J Clin Invest* 2005;115:747-54.

19. Gao J, Shan G, Sun B, ~~Thompson PJ, Gao X.~~ et al. Association between polymorphism of tumour necrosis factor  $\alpha$ -308 gene promoter and asthma: a meta-analysis. *Thorax* 2006 ~~Mar 3~~ ;61:466-71.

20. Wang TN, Chen WY, Wang TH, ~~Chen CJ, Huang LY, Ko YC.~~ et al. Gene-gene synergistic effect on atopic asthma: tumour necrosis factor- $\alpha$ -308 and lymphotoxin- $\alpha$ -NcoI in Taiwan's children. *Clin Exp Allergy* 2004;34:184-8.

21. Shin HD, Park BL, Kim LH, ~~Jung JH, Wang HJ, Kim YJ, Park HS, Hong SJ, Choi BW, Kim DJ, Park CS.~~ et al. Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. *Hum Mol Genet* 2004;13:397-403.

~~24.~~ 22. Hirota T, Suzuki Y, Hasegawa K, ~~Obara K, Matsuda A, Akahoshi M, Nakashima K, Cheng L, Takahashi N, Shimizu M, Doi S, Fujita K, Enomoto T, Ebisawa M, Yoshihara S, Nakamura Y, Kishi F, Shirakawa T, Tamari M.~~ et al.

Functional haplotypes of IL-12B are associated with childhood atopic asthma. *J Allergy Clin Immunol* 2005;116:789-95.

23. Randolph AG, Lange C, Silverman EK, et al. The IL12B gene is associated with asthma. *Am J Hum Genet* 2004;75:709-15.

~~23. Ober C, Hoffjan S. Asthma genetics 2006: the long and winding road to gene discovery. *Genes Immun* 2006; 7:95-100.~~

24. Joos L, Carlen Brutsche IE, Laule-Kilian K, et al. Systemic Th1- and Th2-gene signals in atopy and asthma. *Swiss Med Wkly* 2004;134:159-64.

25. Takahashi N, Akahoshi M, Matsuda A, et al. Association of the IL12RB1 promoter polymorphisms with increased risk of atopic dermatitis and other allergic phenotypes. *Hum Mol Genet* 2005;14:3149-59.

~~22.~~ 26. Park HW, Lee JE, Shin ES, Lee JY, Bahn JW, Oh HB et al. Association between genetic variations of vascular endothelial growth factor receptor 2 and atopy in the Korean population. *J Allergy Clin Immunol* ~~in press.~~ 2006;117:774-9.

~~40.~~ 27. Hill MR, Cookson WO. A new variant of the beta subunit of the high-affinity receptor for immunoglobulin E (Fc epsilon RI-beta E237G): associations with measures of atopy and bronchial hyper-responsiveness. *Hum Mol Genet* 1996;5:959-62.

~~44.~~ 28. Hizawa N, Yamaguchi E, Jinushi E, Kawakami Y. et al. A common FCER1B

gene promoter polymorphism influences total serum IgE levels in a Japanese population.

*Am J Respir Crit Care Med* 2000;161:906-9.

29. Hytonen AM, Lowhagen O, Arvidsson M, et al. Haplotypes of the interleukin-4 receptor alpha chain gene associate with susceptibility to and severity of atopic asthma. *Clin Exp Allergy* 2004;34:1570-5.

30. Seegers D, Zwiers A, Strober W, et al. A TaqI polymorphism in the 3'UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. *Genes Immun* 2002;3:419-23.

31. Akahoshi M, Nakashima H, Miyake K, et al. Influence of interleukin-12 receptor beta1 polymorphisms on tuberculosis. *Hum Genet* 2003;112:237-43.

~~25. Han W, Kang D, Park IA, Kim SW, Bae JY, Chung KW, Noh DY. Associations between breast cancer susceptibility gene polymorphisms and clinicopathological features. *Clin Cancer Res* 2004; 10(1 Pt 1):124-30.~~

~~26. Lee SG, Kim BS, Kim JH, Lee SY, Choi SO, Shim JY, Hong TJ, Hong SJ. Gene-gene interaction between interleukin-4 and interleukin-4 receptor alpha in Korean children with asthma. *Clin Exp Allergy* 2004; 34:1202-8.~~

~~27. Wang TN, Chen WY, Wang TH, Chen CJ, Huang LY, Ko YC. Gene-gene synergistic effect on atopic asthma: tumour necrosis factor alpha-308 and~~

~~lymphotoxin-alpha-Neol in Taiwan's children. Clin Exp Allergy 2004;34:184-8.~~

~~28~~ 32. Hong SJ, Lee SY, Kim HB, ~~Kim JH, Kim BS, Choi SO, Lee SG, Shin ES, Hong TJ.~~ et al. IL-5 and thromboxane A2 receptor gene polymorphisms are associated with decreased pulmonary function in Korean children with atopic asthma. *J Allergy Clin Immunol* 2005;**115**:758-63.

~~29~~ 33. Clauss M. Molecular biology of the VEGF and the VEGF receptor family. *Semin Thromb Hemost* 2000;**26**:561-9.

~~30~~ 34. Antony AB, Tepper RS, Mohamed KA. Cockroach extract antigen increases bronchial epithelial permeability. *J Allergy Clin Immunol* 2002;**110**:589-95.

~~31~~ 35. Matsui EC, Wood RA, Rand C, ~~Kanchanaraks S, Swartz L, Curtin Brosnan J, Eggleston PA.~~ et al. Cockroach allergen exposure and sensitization in suburban middle-class children with asthma *J Allergy Clin Immunol* 2003;**112**:87-92.

~~32~~ 36. Wright RJ, Finn P, Contreras JP, ~~Cohen S, Wright RO, Staudenmayer J, Wand M, Perkins D, Weiss ST, Gold DR.~~ et al. Chronic caregiver stress and IgE expression, allergen-induced proliferation, and cytokine profiles in a birth cohort predisposed to atopy. *J Allergy Clin Immunol* 2004;**113**:1051-7.

~~33~~ 37. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. *Science* 1996;**272**:50-3.

~~34~~ 38. Okumura S, Kashiwakura J, Tomita H, ~~Matsumoto K, Natkajima T, Saito H,~~  
et al. Identification of specific gene expression profiles in human mast cells mediated by  
Toll-like receptor 4 and FcepsilonRI. *Blood* 2003;**10**:2547-54.

~~34~~ 39. Iwasaki M, Saito K, Takemura M, ~~Sekikawa K, Fujii H, Yamada Y,~~ et al.  
TNF-alpha contributes to the development of allergic rhinitis in mice. *J Allergy Clin  
Immunol* 2003;**112**:134-40.

~~35~~ 40. Hangai M, He S, Hoffmann S, ~~Lim H, Ryan SJ, Hinton DR,~~ et al. Sequential  
induction of angiogenic growth factors by TNF-alpha in choroidal endothelial cells *J  
Neuroimmunol* 2006;**171**:45-56.

~~36~~ 41. Yoo SA, Bae DG, Ryoo JW, ~~Kim HR, Park GS, Cho CS, Chae CB, Kim WU,~~  
et al. Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide  
inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and  
IL-6 by human monocytes. *J Immunol* 2005;**174**:5846-55.

**Table 1 Candidate genes and SNPs analyzed in this study**

<b>Gene</b>	<b>SNP</b>	<b>Association</b>
<i>FcεR1B</i> <sup>*</sup>	E237G	atopy <sup>10</sup> , IgE <sup>10,11</sup>
<i>IL4R</i>	3223T>C, Q576R, I75V	atopy <sup>12-14</sup> , IgE <sup>15,16</sup>
<i>IL13</i>	1510A>C, 1111C>T, R130Q	atopy <sup>14,17</sup> , IgE <sup>14,18</sup>
<i>TNFα</i>	308G>A	atopy <sup>19,20</sup> , IgE <sup>21</sup>
<i>VEGFR2</i> <sup>†</sup>	I297V, H472Q	atopy <sup>22</sup>
<i>IL12B</i>	S226N	atopy <sup>23</sup>
<i>IL12R1B</i>	M356T	atopy <sup>24</sup>

<sup>\*</sup>*FcεR1B*: high affinity IgE receptor beta subunit

<sup>†</sup>*VEGFR2*: Vascular growth factor receptor 2

**Table 1 Candidate genes and SNPs analyzed in this study**

<u>Gene</u>	<u>SNP</u>	<u>rs number</u>	<u>Association</u>
<u>IL4R</u>	<u>-3223T&gt;C</u>	<u>rs2057768</u>	<u>atopy<sup>11-13</sup>, IgE<sup>14</sup></u>
	<u>Q576R</u>	<u>rs1801275</u>	
	<u>I75V</u>	<u>rs1805010</u>	
<u>IL13</u>	<u>-1510A&gt;C</u>	<u>rs1881457</u>	<u>atopy<sup>16,17</sup>, IgE<sup>15,18</sup></u>
	<u>-1111C&gt;T</u>	<u>rs1800925</u>	
	<u>Q144R</u>	<u>rs20541</u>	
<u>TNF</u>	<u>-308G&gt;A</u>	<u>rs1800629</u>	<u>atopy<sup>19,20</sup>, IgE<sup>21</sup></u>
<u>IL12B</u>	<u>S226N</u>	<u>=</u>	<u>atopy<sup>22,23</sup></u>
<u>IL12RB1</u>	<u>M365T</u>	<u>rs375947</u>	<u>atopy<sup>24,25</sup></u>
<u>KDR*</u>	<u>V297I</u>	<u>rs2305948</u>	<u>atopy<sup>26</sup></u>
	<u>H472Q</u>	<u>rs1870377</u>	
<u>MS4A2<sup>‡</sup></u>	<u>E237G</u>	<u>rs569108</u>	<u>atopy<sup>27,28</sup>, IgE<sup>27,28</sup></u>

**\* KDR: gene coding vascular growth factor receptor 2**

**‡MS4A2: gene coding high affinity IgE receptor beta subunit**

**Table 2. The characteristics of study population**

<b><u>Characteristics</u></b>	<b><u>Number of positivity (%)</u></b>
<b><u>Age, mean (range)</u></b>	<b><u>14.6 (10-18)</u></b>
<b><u>Male</u></b>	<b><u>1004 (48.9%)</u></b>
<b><u>Atopy*</u></b>	<b><u>767 (37.3%)</u></b>
<b><u>History of passive smoking</u></b>	<b><u>1342 (65.3%)</u></b>
<b><u>Family history of allergic disease</u></b>	<b><u>376 (18.3%)</u></b>
<b><u>Vaccination history</u></b>	<b><u>1552 (75.5%)</u></b>

**\* Positive skin test responses to one or more common aeroallergens.**

Table 3. Genetic effects of individual SNP on atopy

	Genotype frequency			<i>P</i> value*		
				Dominant <sup>†</sup>	Recessive <sup>†</sup>	Co-dominant <sup>†</sup>
<b><i>IL4R</i></b>						
<b>-3223T&gt;C</b>						
	TT	TC	CC			
Atopy	278 (38.0%)	346 (47.3%)	108 (14.7%)	<u>0.130</u>	<u>0.413</u>	<u>0.301</u>
Control	515 (41.4%)	561 (45.1%)	167 (13.5%)			
<b><del><i>IL4R</i></del> Q576R</b>						
	QQ	QR	RR			
Atopy	529 (69.2%)	214 (28.0%)	21 (2.8%)	<u>0.831</u>	<u>0.426</u>	<u>0.728</u>
Control	895 (68.8%)	362 (27.8%)	44 (3.4%)			
<b><del><i>IL4R</i></del> V75I</b>						
	VV	VI	II			
Atopy	244 (31.9%)	378 (49.5%)	142 (18.6%)	<u>0.789</u>	<u>0.283</u>	<u>0.214</u>
Control	461 (35.5%)	619 (47.7%)	217 (16.8%)			
<b><i>IL13</i></b>						
<b>-1510A&gt;C</b>						
	AA	AC	CC			
Atopy	381 (53.4%)	267 (36.5%)	65 (10.1%)	<u>0.630</u>	<u>0.170</u>	<u>0.248</u>
Control	646 (52.3%)	498 (40.3%)	91 (7.4%)			
<b><del><i>IL13</i></del> -1111C&gt;T</b>						
	CC	CT	TT			
Atopy	478 (67.3%)	203 (28.6%)	29 (4.1%)	<u>0.614</u>	<u>0.907</u>	<u>0.880</u>

Control 805 (66.2%) 360 (29.6%) 51 (4.2%)

~~HL3~~ **R130Q**

	RR	RQ	QQ			
Atopy	364 (47.5%)	334 (43.5%)	69 (9.0%)	<u>0.631</u>	<u>0.891</u>	<u>0.853</u>
Control	628 (48.7%)	546 (42.4%)	114 (8.9%)			

~~TNF $\alpha$~~  **TNF**

**-308G>A**

	GG	GA	AA			
Atopy	606 (82.6%)	126 (17.2%)	2 (0.2%)	<u>0.031</u>	<u>0.857</u>	<u>0.043</u>
Control	1083 (86.2%)	170 (13.5%)	4 (0.3%)			

~~VEGFR2~~ **KDR**

**V297I**

	VV	VI	II			
Atopy	543 (71.3%)	206 (27.1%)	12 (1.6%)	<u>0.048</u>	<u>0.212</u>	<u>0.029</u>
Control	976 (75.3%)	289 (22.3%)	31 (2.4%)			

~~VEGFR2~~ **H472Q**

	HH	HQ	QQ			
Atopy	256 (33.7%)	355 (46.8%)	148 (19.5%)	<u>0.559</u>	<u>0.698</u>	<u>0.827</u>
Control	451 (35.1%)	597 (46.4%)	240 (18.5%)			

**IL12B**

**S226N**

	SS	SN	NN			
Atopy	724 (94.3%)	43 (5.7%)	0 (0%)	<u>0.744</u>	-	<u>0.748</u>
Control	1230 (95.5%)	58 (4.5%)	0 (0%)			

***IL12R+~~B1~~***

**~~M356T~~ M365T**

	MM	MT	TT			
Atopy	247 (32.8%)	351 (46.6%)	155 (20.6%)	<u>0.845</u>	<u>0.555</u>	<u>0.767</u>
Control	420 (32.4%)	624 (48.1%)	253 (19.5%)			

**~~FcεR1B~~ MS4A2**

**E237G**

	EE	EG	GG			
Atopy	568 (80.8%)	120 (17.7%)	15 (1.5%)	<u>0.076</u>	<u>0.129</u>	<u>0.028</u>
Control	936 (77.4%)	259 (21.4%)	15 (1.2%)			

---

\*P values for logistic analyses controlling age, sex, a family history of allergic diseases, passive smoking history, and vaccination history

†Dominant model (AA vs. AB+BB), Recessive model (AA+AB vs. BB), and Co-dominant model (AA vs. AB vs. BB), where A is the major frequency allele and B is the minor frequency allele

Table 3.4. Summary of multiloci interaction for atopy by MDR analysis

No. of loci	Combination of SNPs	CV consistency	Prediction error (%)
2	-308G>A ( <del>TNF<math>\alpha</math></del> <u>TNF</u> ), V297I ( <del>VEGFR2</del> <u>KDR</u> )	10	35.93
3	-308G>A ( <del>TNF<math>\alpha</math></del> <u>TNF</u> ), V297I ( <del>VEGFR2</del> <u>KDR</u> ), Q576R ( <i>IL4R</i> )	3	35.44
4	E237G ( <del>Fc<math>\epsilon</math>R1B</del> <u>MS4A2</u> ), V297I ( <del>VEGFR2</del> <u>KDR</u> ), I75V ( <i>IL4R</i> ), -1510A>C ( <i>IL13</i> ),	4	39.39
5	I75V ( <i>IL4R</i> ), R130Q ( <i>IL13</i> ), <del>M356T</del> <u>M365T</u> ( <i>IL12R</i> <del><math>\beta</math></del> <u>1</u> ), H472Q ( <del>VEGFR2</del> <u>KDR</u> ), S226N ( <i>IL12B</i> )	8	39.41

**Table 5. Interactions between *TNF* and *KDR* genotypes for atopy.**

<u>Genotype</u>		<u>Phenotype</u>		<u>P value*</u>	<u>OR (95%CI)</u>
<u><i>TNF</i> (-308G&gt;A)</u>	<u><i>KDR</i> (V297I)</u>	<u>atopy</u>	<u>control</u>		
<u>GG</u>	<u>VV</u>	<u>434 (35.0%)</u>	<u>806 (65.0%)</u>		<u>1</u>
<u>GG</u>	<u>VI or II</u>	<u>81 (37.5%)</u>	<u>135 (62.5%)</u>	<u>0.53</u>	<u>1.11 (0.83-1.50)</u>
<u>GA or AA</u>	<u>VV</u>	<u>166 (38.5%)</u>	<u>265 (61.5%)</u>	<u>0.21</u>	<u>1.16 (0.93-1.46)</u>
<u>GA or AA</u>	<u>VI or II</u>	<u>47 (55.3%)</u>	<u>38 (44.7%)</u>	<u>&lt; 0.001</u>	<u>2.30 (1.48-3.57)</u>

**\*P values for logistic analyses controlling age, sex, a family history of allergic diseases, passive smoking history, and vaccination history**

**Table S1 The minor allele frequencies of SNPs compared to those previously reported**

<u>SNP</u>	<u>Minor allele frequency</u>	
	<u>Present study</u>	<u>Previous reports (population and reference)</u>
<u><i>IL4R</i></u>		
<u>-3223T&gt;C</u>	<u>37.2 %</u>	<u>10.7 % (Swedish healthy adults, ref. 29)</u>
<u>Q576R</u>	<u>16.8 %</u>	<u>22.0 % (Japanese healthy adults, ref. 13)</u> <u>30.5 % (American asthmatics, ref. 12)</u>
<u>I75V</u>	<u>41.6 %</u>	<u>40.4 % (Japanese healthy adults, ref. 14)</u> <u>42.0 % (American asthmatics, ref. 12)</u>
<u><i>IL13</i></u>		
<u>-1510A&gt;C</u>	<u>28.0 %</u>	<u>22.0 % (American healthy adults, ref. 15)</u>
<u>-1111C&gt;T</u>	<u>18.9 %</u>	<u>23.0 % (American healthy adults, ref. 15)</u>
<u>Q144R</u>	<u>30.8 %</u>	<u>40.8 % (Chinese healthy children, ref. 16)</u> <u>26.7 % (British healthy adults, ref. 13)</u>
<u><i>TNF</i></u>		
<u>-308G&gt;A</u>	<u>7.7 %</u>	<u>7.0 % (Taiwanese healthy children, ref. 20)</u> <u>12.9 % (Czech healthy adults, ref. 19)</u>

**IL12B**

S226N      3.6 %      4.0 % (Japanese asthmatics<sup>‡</sup>)

**IL12RB1**

M365T      33.0 %      36.2 % (Japanese healthy adults, ref. 31)

**KDR\***

V297I      14.2 %      =

H472Q      42.6 %      =

**MS4A2<sup>‡</sup>**

E237G      11.7 %      5.3 % (Australian healthy adults, ref. 27)

11.5 % (Japanese healthy adults<sup>¶</sup>)

---

\* **KDR: gene coding vascular growth factor receptor 2**

‡ **MS4A2: gene coding high affinity IgE receptor beta subunit**

‡ **Noguchi E, Yokouchi Y, Shibasaki M, et al. Identification of missense mutation in the IL12B gene: lack of association between IL12B polymorphisms and asthma and allergic rhinitis in the Japanese population. Genes Immun 2001; 2:401-3**

¶ **Nagata H, Mutoh H, Kumahara K, et al. Association between nasal allergy and a coding variant of the Fc epsilon RI beta gene Glu237Gly in a Japanese population. Hum Genet 2001; 109:262-6.**

## Figure legends

Figure 1. Distribution of high-risk and low-risk genotypes in the best two-locus model.

This summary of the distribution shows high-risk (dark shading) and low-risk (light shading) genotypes associated with atopy in the two-locus interaction detected by MDR analysis. The percentage of atopic subjects (left black bar in boxes) and control subjects (right hatched bar in boxes) is shown for each two-locus genotype combination. The white boxes are unclassified.

~~Figure 2. Interactions between *TNF $\alpha$*  and *VEGFR2* genotypes for atopy. Bars indicate the ORs between the different combinations of genotypes for *TNF $\alpha$*  (308G>A) and *VEGFR2* (V297I). The non-risk genotype for each gene was used as the reference OR.~~

Figure 1.

